Monday, June 22, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 540 of 1,261

  1. US 10092504

    Use of cellular extracts for skin rejuvenation

    REGENICS AS · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  2. US 10093708

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  3. US 10093684

    Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  4. US 10093664

    Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  5. US 10092583

    Imidazopyridines Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  6. US 10092512

    Compositions and methods of making brittle-matrix particles through blister pack freezing

    The Board of Regents of the University of Texas System · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  7. US 10092559

    Abuse resistant pharmaceutical compositions

    RECRO GAINESVILLE LLC · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  8. US 10093900

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  9. US 10094836

    SLCO1B3 genotype

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  10. US 10093899

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  11. US 10093790

    Three-dimensional cellulose molded body, method for the production thereof and use of the same

    LENZING AKTIENGESELLSCHAFT · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  12. US 10093686

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  13. US 10093698

    Peptide having efficacy for remedying hypopigmentation and inhibiting adipogenesis, and use of same

    CAREGEN CO., LTD. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  14. US 10093710

    Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  15. US 10093694

    Compounds for treating eye disorders or diseases

    The Regents of the University of California · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  16. US 10093676

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  17. US 10093641

    Process for making beraprost

    United Therapeutics Corporation · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  18. US 10093668

    Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)

    Northwestern University · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  19. US 10093654

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  20. US 10093742

    Multispecific GITR-binding fusion proteins and methods of use thereof

    Inhibrx, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  21. US 10093629

    Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

    Takeda Pharmaceutical Company Limited · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  22. US 10092736

    Device and method for dispensing a drug

    Demira, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  23. US 10092656

    Protease inhibitors having enhanced features

    Nektar Therapeutics · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  24. US 10092637

    Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.